Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four...
Read moreDetails
First Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities Conference
BOCA RATON, Fla., Oct. 03, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the...
Read moreDetailsRegeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies...
Read moreDetailsRegeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies...
Read moreDetailsRegrow Ag Welcomes Dan Pasette as Chief Technology Officer
Accomplished Engineering Leader Joins TIME100 Most Influential Company Regrow Ag CTO Dan Pasette, CTO, Regrow Ag SAN FRANCISCO, Oct. 03,...
Read moreDetailsOneWater Marine Inc. Announces Strategic Relationship with Bradford Marine
OneWater Yacht Group and Bradford Marine to provide premium sales and service experience to yacht owners at the Roscioli Yachting...
Read moreDetailsRemoteBridge Set to Showcase Award-Winning Immersive 3D Platform at HR Technology Conference & Exposition
SANTA BARBARA, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- WHO:RemoteBridge, the immersive 3D platform helping HR and TA leaders build...
Read moreDetailsPDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)
Interim VERSATILE-002 data for the first-line treatment of recurrent or metastatic head and neck cancer patients who were immune checkpoint...
Read moreDetailsNext Week’s HR Technology Conference & Exposition® to Feature Industry’s Biggest Expo Ever
Eagerly Awaited Event Reigns as Preeminent Launchpad for New ProductsPALM BEACH GARDENS, Fla., Oct. 03, 2023 (GLOBE NEWSWIRE) -- As...
Read moreDetailsVerano Receives Conditional Approval to List on the Cboe Canada
CHICAGO, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading...
Read moreDetailsADVERTISEMENTS
